As IC/BPS might be multifactorial, future research should target different implicated pathways simultaneously and study the role of reactive oxygen species as a root cause in IC/BPS
Freezing a reconstituted peptide can destroy its structure
Hierarchy of Evidence: Level A (Human meta-analyses and systematic reviews of CNS drug delivery)
Most people need at least eight to twelve weeks to see steady change
Combination research has examined whether simultaneous BPC-157 and TB-500 administration produces wound healing enhancement exceeding either peptide alone
Methods: SISTER (NCT05948566) is an ongoing, Phase 2, prospective, randomized, placebo-controlled, blinded, adaptive dose-finding clinical trial that aims to identify a dose of TS23 that is safe and potentially more efficacious than placebo